Reported about 2 months ago
A recent study shows that Eli Lilly's weight-loss drug tirzepatide, known as Mounjaro and Zepbound, can cut the long-term risk of developing Type 2 diabetes by an impressive 94%, leading to a rise in the company's stock value.
Source: YAHOO